Azacitidine in 302 patients with WHO-defined acute myeloid leukemia: results from the Austrian Azacitidine Registry of the AGMT-Study Group

Annals of Hematology

Volumn 93, Issue 11, 2014, Pages 1825-1838

  Pleyer, Lisa ^a   Burgstaller, Sonja ^b   Girschikofsky, Michael ^c   Linkesch, Werner ^d   Stauder, Reinhard ^e   Pfeilstocker, Michael ^f   Schreder, Martin ^g   Tinchon, Christoph ^h   Sliwa, Thamer ⁱ   Lang, Alois ^j   Sperr, Wolfgang R ^k   Krippl, Peter ^h   Geissler, Dietmar ^l   Voskova, Daniela ^m   Schlick, Konstantin ^a   Thaler, Josef ^b   Machherndl Spandl, Sigrid ^c   Theiler, Georg ^d   Eckmüllner, Otto ⁿ   Greil, Richard ^a  

^a PARACELSUS MEDICAL UNIVERSITY   (Austria)

^b Hospital Wels Grieskirchen   (Austria)

^c ELISABETHINEN HOSPITAL   (Austria)

^d MEDICAL UNIVERSITY OF GRAZ   (Austria)

^e INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^f HANUSCH HOSPITAL   (Austria)

^g WILHELMINEN HOSPITAL   (Austria)

^h LKH Leoben Eisenerz ^*  (Austria)

ⁱ 5th Medical Department with Oncology und Palliative Medicine   (Austria)

^j Hospital Feldkirch   (Austria)

^k MEDICAL UNIVERSITY OF VIENNA   (Austria)

^l Klinikum Klagenfurt am Wörtersee   (Austria)

^m KEPLER UNIVERSITY HOSPITAL   (Austria)

ⁿ UNIVERSITY OF NATURAL RESOURCES AND LIFE SCIENCES   (Austria)

more..

Author keywords

AML; Austrian Azacitidine Registry; Azacitidine; Bone marrow blasts; Overall survival; Prognostic factors

Indexed keywords

ANTIANEMIC AGENT; ANTIFUNGAL AGENT; ANTIVIRUS AGENT; AZACITIDINE; CYTARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; HEMATOLOGIC AGENT; HYDROXYUREA; IRON CHELATING AGENT; LENALIDOMIDE; THALIDOMIDE; THROMBOPOIETIN STIMULATING AGENT; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG; ANTINEOPLASTIC ANTIMETABOLITE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ANEMIA; ANGINA PECTORIS; ARTICLE; BLAST CELL; BLEEDING; CANCER PATIENT; CANCER PROGNOSIS; CANCER REGISTRY; CANCER SURVIVAL; CARDIOTOXICITY; COHORT ANALYSIS; CONSTIPATION; DIARRHEA; DRUG DOSE REDUCTION; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL SYMPTOM; HEART ARRHYTHMIA; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HUMAN; HYPERTENSION; INFECTION; INFECTIOUS COMPLICATION; INJECTION SITE REACTION; LEUKEMIA REMISSION; LEUKOCYTE COUNT; LIVER TOXICITY; LOW DRUG DOSE; LUNG INFECTION; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; MULTIPLE CYCLE TREATMENT; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PAIN; PYREXIA IDIOPATHICA; SOLID TUMOR; THROMBOCYTOPENIA; THROMBOEMBOLISM; TREATMENT RESPONSE; VOMITING; AUSTRIA; CLINICAL TRIAL; EPIDEMIOLOGY; LEUKEMIA, MYELOID, ACUTE; MIDDLE AGED; MULTICENTER STUDY; REGISTER; RETROSPECTIVE STUDY; SURVIVAL RATE; TREATMENT OUTCOME; TRENDS; VERY ELDERLY; WORLD HEALTH ORGANIZATION;

ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; AUSTRIA; AZACITIDINE; COHORT STUDIES; FEMALE; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; REGISTRIES; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME; WORLD HEALTH ORGANIZATION;

EID: 84919717456     PISSN: 09395555     EISSN: 14320584     Source Type: Journal    
DOI: 10.1007/s00277-014-2126-9     Document Type: Article

References (25)

1. Lowenberg B (2001) Prognostic factors in acute myeloid leukaemia. Best Pract Res Clin Haematol 14(1):65–75
2. Stone RM (2002) The difficult problem of acute myeloid leukemia in the older adult. CA Cancer J Clin 52(6):363–371
3. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Finelli C, Giagounidis A et al (2009) Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 10(3):223–232
4. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Gattermann N, Germing U et al (2010) Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol 28(4):562–569
5. Al Ali HK, Jaekel N, Junghanss C, Maschmeyer G, Krahl R, Cross M et al (2012) Azacitidine in patients with acute myeloid leukemia medically unfit for or resistant to chemotherapy: a multicenter phase I/II study. Leuk Lymphoma 53(1):110–117
6. Gavillet M, Noetzli J, Blum S, Duchosal MA, Spertini O, Lambert JF (2012) Transfusion independence and survival in patients with acute myeloid leukemia treated with 5-azacytidine. Haematologica 97(12):1929–1931
7. Maurillo L, Venditti A, Spagnoli A, Gaidano G, Ferrero D, Oliva E et al (2012) Azacitidine for the treatment of patients with acute myeloid leukemia: report of 82 patients enrolled in an Italian compassionate program. Cancer 118(4):1014–1022
8. Pleyer L, Stauder R, Burgstaller S, Schreder M, Tinchon C, Pfeilstocker M et al (2013) Azacitidine in patients with WHO-defined AML—results of 155 patients from the Austrian Azacitidine Registry of the AGMT-Study Group. J Hematol Oncol 6(1):32
9. Silverman LR, McKenzie DR, Peterson BL, Holland JF, Backstrom JT, Beach CL et al (2006) Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. J Clin Oncol 24(24):3895–3903
10. Sudan N, Rossetti JM, Shadduck RK, Latsko J, Lech JA, Kaplan RB et al (2006) Treatment of acute myelogenous leukemia with outpatient azacitidine. Cancer 107(8):1839–1843
11. Thepot S, Itzykson R, Seegers V, Raffoux E, Quesnel B, Chait Y et al (2010) Treatment of progression of Philadelphia negative myeloproliferative neoplasms to myelodysplastic syndrome or acute myeloid leukemia by azacitidine: a report on 54 cases on the behalf of the Groupe Francophone des Myelodysplasies. Blood 116(19):3735–3742
12. Thepot S, Itzykson R, Seegers V, Recher C, Raffoux E, Quesnel B et al (2014) Azacitidine in untreated acute myeloid leukemia. A report on 149 patients. Am J Hematol 89(4):410–416
13. van der Helm LH, Alhan C, Wijermans PW, van Marwijk KM, Schaafsma R, Biemond BJ et al (2011) Platelet doubling after the first azacitidine cycle is a promising predictor for response in myelodysplastic syndromes (MDS), chronic myelomonocytic leukaemia (CMML) and acute myeloid leukaemia (AML) patients in the Dutch azacitidine compassionate named patient programme. Br J Haematol 155(5):599–606
14. van der Helm LH, Veeger NJ, Kooy M, Beeker A, de Weerdt O, de Groot M et al (2013) Azacitidine results in comparable outcome in newly diagnosed AML patients with more or less than 30 % bone marrow blasts. Leuk Res 37(8):877–882
15. Pleyer L, Germing U, Sperr WR, Linkesch W, Burgstaller S, Stauder R et al (2014) Azacitidine in CMML: matched-pair analyses of daily-life patients reveal modest effects on clinical course and survival. Leuk Res 38(4):475–483
16. Cheson BD, Bennett JM, Kopecky KJ, Buchner T, Willman CL, Estey EH et al (2003) Revised recommendations of the International Working Group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol 21(24):4642–4649
17. Cheson BD, Greenberg PL, Bennett JM, Lowenberg B, Wijermans PW, Nimer SD et al (2006) Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood 108(2):419–425
18. Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G et al (1998) The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children’s Leukaemia Working Parties. Blood 92(7):2322–2333
19. Dombret H, Raffoux E, Gardin C (2008) Acute myeloid leukemia in the elderly. Semin Oncol 35(4):430–438
20. Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G et al (1997) International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89(6):2079–2088
21. Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG et al (2005) Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 106(8):2912–2919
22. Kayser S, Zucknick M, Dohner K, Krauter J, Kohne CH, Horst HA et al (2012) Monosomal karyotype in adult acute myeloid leukemia: prognostic impact and outcome after different treatment strategies. Blood 119(2):551–558
23. Breems DA, Van Putten WL, De Greef GE, Zelderen-Bhola SL, Gerssen-Schoorl KB, Mellink CH et al (2008) Monosomal karyotype in acute myeloid leukemia: a better indicator of poor prognosis than a complex karyotype. J Clin Oncol 26(29):4791–4797
24. Breems DA, Lowenberg B (2011) Acute myeloid leukemia with monosomal karyotype at the far end of the unfavorable prognostic spectrum. Haematologica 96(4):491–493
25. Thepot S (2009) IRSVRCQBDJCTeal. Azacytidine (AZA) as first line therapy in AML: results of the French ATU Program. Blood 114(22):843